• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.620 +0.040 (+2.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 371,744
Open 1.590
Bid (Size) 1.600 (5)
Ask (Size) 1.630 (10)
Prev. Close 1.580
Today's Range 1.560 - 1.900
52wk Range 0.8900 - 3.190
Shares Outstanding 27,132,588
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
July 16, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
July 16, 2025
Via Benzinga

Performance

YTD
-30.2%
-30.2%
1 Month
-4.1%
-4.1%
3 Month
-12.4%
-12.4%
6 Month
-25.7%
-25.7%
1 Year
+39.7%
+39.7%

More News

Read More
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus
July 16, 2025
Via Benzinga
Topics Economy
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
July 16, 2025
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 15, 2025
Via Benzinga
Tuesday's after hours session: top gainers and losers
July 15, 2025
Via Chartmill
Gain Therapeutics Announces Proposed Public Offering
July 15, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
June 30, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in Upcoming Investor Conferences
June 10, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
May 29, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
May 14, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
May 12, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
May 01, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
April 30, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
April 10, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 01, 2025
Via Benzinga
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
March 28, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
March 27, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
March 14, 2025
Via Get News
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
March 14, 2025
Via ACCESS Newswire
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
March 14, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
March 06, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
February 06, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics To Participate in Upcoming Investor Conferences
February 05, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
January 08, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Gain Therapeutics, Inc. - Common Stock publicly traded?
Yes, Gain Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Gain Therapeutics, Inc. - Common Stock trade on?
Gain Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Gain Therapeutics, Inc. - Common Stock?
The ticker symbol for Gain Therapeutics, Inc. - Common Stock is GANX on the Nasdaq Stock Market
What is the current price of Gain Therapeutics, Inc. - Common Stock?
The current price of Gain Therapeutics, Inc. - Common Stock is 1.620
When was Gain Therapeutics, Inc. - Common Stock last traded?
The last trade of Gain Therapeutics, Inc. - Common Stock was at 07/22/25 04:00 PM ET
What is the market capitalization of Gain Therapeutics, Inc. - Common Stock?
The market capitalization of Gain Therapeutics, Inc. - Common Stock is 43.95M
How many shares of Gain Therapeutics, Inc. - Common Stock are outstanding?
Gain Therapeutics, Inc. - Common Stock has 44M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap